CHA₂DS₂-VASc Score
Estimates annual stroke risk in non-valvular atrial fibrillation to guide anticoagulation.
How to use & interpret
The CHA₂DS₂-VASc score estimates annual ischaemic stroke risk in non-valvular atrial fibrillation and is the standard tool for deciding who should be offered oral anticoagulation. It is calculated once AF is confirmed, irrespective of whether the AF is paroxysmal, persistent or permanent.
UK/ESC practice: consider anticoagulation at a score of ≥1 in men and ≥2 in women, and offer it at ≥2 in men / ≥3 in women, after discussing bleeding risk (e.g. with HAS-BLED). A score of 0 in men (1 in women, from sex alone) is genuinely low risk and does not warrant anticoagulation. Antiplatelet monotherapy is no longer recommended for stroke prevention in AF.
Score interpretation
Score 0: low annual stroke risk (~0 %).
→ No antithrombotic therapy for stroke prevention; reassess at each visit.
Score 1 (annual stroke risk ~1.3 %). ESC 2020: men — oral anticoagulation should be considered (IIa); women whose only point is female sex — low risk, no anticoagulation.
→ Shared decision on anticoagulation for men; reassess women as risk factors change.
Score 2 (annual stroke risk ~2.2 %). ESC 2020: men — oral anticoagulation recommended (I); women — should be considered (IIa).
→ DOAC in preference to warfarin unless contraindicated; assess bleeding risk (HAS-BLED).
Score ≥ 3: oral anticoagulation recommended for men and women (ESC 2020, Class I).
→ DOAC in preference to warfarin unless contraindicated; assess bleeding risk (HAS-BLED).
Interpretation bands for the CHA₂DS₂-VASc. Apply clinical judgement and local guidance.
Frequently asked questions
Should I use CHA₂DS₂-VASc or CHA₂DS₂-VA?
The 2024 ESC guideline moved to CHA₂DS₂-VA (dropping the sex category) to simplify decisions, but CHA₂DS₂-VASc remains widely used and validated. The clinically important threshold (treat at a score reflecting ≥2 non-sex risk factors) is unchanged.
Does a high score mandate anticoagulation?
It prompts a shared decision, weighed against bleeding risk and patient preference. The score quantifies stroke risk; it does not by itself account for fall risk, adherence, or contraindications.
References
- Lip GY et al. Refining clinical risk stratification for predicting stroke. Chest. 2010.
- ESC Guidelines for Atrial Fibrillation, 2020.
Related
Curated clinical cross-links plus same-class fallbacks.
- ORBIT Bleeding Risk Score for AF · Atrial Fibrillation
- CHA₂DS₂-VA Score for AF (ESC 2024) · Atrial Fibrillation
- CHADS-65 for Atrial Fibrillation · Atrial Fibrillation
- GARFIELD-AF Risk Score for Atrial Fibrillation · Atrial Fibrillation
- CHADS-65 Score for Atrial Fibrillation · Atrial Fibrillation
- CHARGE-AF Score for Incident Atrial Fibrillation · Atrial Fibrillation
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Vernakalant · Atrial-selective antiarrhythmic
- Aspirin (Loading Dose) · Antiplatelet — ACS / Ischaemic Stroke
- Alteplase (tPA) · Thrombolytic — Ischaemic Stroke / Massive PE
- Bivalirudin · Anticoagulation
- Edoxaban (AF Stroke Prevention / VTE) · Direct Factor Xa Inhibitor (DOAC)
- New-Onset Atrial FibrillationUsed in pathwayESC 2020 AF Guidelines; NICE NG196
- Chronic Atrial Fibrillation ManagementUsed in pathwayNICE NG196; ESC 2024 AF Guidelines
- Atrial Flutter ManagementUsed in pathwayESC 2024 AF/flutter; AHA/ACC/HRS
- Peri-Arrest Tachyarrhythmia (Adult)Used in pathwayRCUK 2021 Adult Tachycardia Algorithm
Featured in these MRCEM clinical pathways
The CHA₂DS₂-VASc is covered in detail — with RCEM/NICE evidence base, indications and pitfalls — in the following exam-focused pathways on our sister siteReviseMRCEM.
MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.